drugset / Trial / NCT05860374

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors

NCT05860374 ↗

NaSingle-groupOpen-labelTreatment

Summary

20 participants are expected to be enrolled for this open,Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced solid tumors.

Timeline

Start
2023-03-02
Primary completion
2025-03-02
Completion
2026-03-02

Drugs

EvaluationDrugModalityDoseRoute
Subject R130 Unknown — Other